Contract A207_PO-0471667

Life Technologies Corporation was awarded a contract by the University of Virginia on August 21, 2026, for the delivery of MG 132, a proteasome inhibitor compound commonly used in laboratory research applications. The contract, designated A207_PO-0471667, specifies a single unit delivery to Matthew S. Loftus with a unit price of $49.20, resulting in a cumulative contract value of forty-nine dollars. The award represents a straightforward procurement of research materials by the Virginia-based educational institution.

No specific period of performance, ongoing service terms, or place of performance beyond the identified recipient are detailed in the contract documentation. The contract's minimal value and singular line item suggest this represents a discrete purchase order for laboratory supplies rather than a comprehensive service engagement. As a Virginia state educational institution, the University of Virginia served as the contracting organization for this acquisition from the prime contractor.